A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma
Randomized Phase III Trial of Chemotherapy vs. Pembrolizumab Plus Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma
Study Overview
Status
Intervention / Treatment
- Drug: Carboplatin
- Drug: Etoposide
- Drug: Ifosfamide
- Drug: Pegylated Liposomal Doxorubicin Hydrochloride
- Radiation: Radiation Therapy
- Drug: Gemcitabine
- Biological: Pembrolizumab
- Drug: Brentuximab Vedotin
- Procedure: Autologous Hematopoietic Stem Cell Transplantation
- Drug: Bendamustine
- Procedure: Positron Emission Tomography
- Drug: Vinorelbine
- Procedure: Computed Tomography
- Other: Transplant Conditioning
Detailed Description
PRIMARY OBJECTIVE:
I. To assess the 2-year event free survival (EFS) of patients treated with pembrolizumab added to chemotherapy versus chemotherapy alone, in patients with relapsed/refractory (R/R) classical Hodgkin's lymphoma (cHL) who are intended to receive salvage therapy followed by high dose chemotherapy and autologous stem cell transplant (HDT-ASCT).
PRIMARY IMAGING OBJECTIVE:
I. To assess the diagnostic performance of baseline total metabolic tumor volume (TMTV) in predicting response (complete remission [CR] + partial remission [PR] versus [vs] no response) at pre-transplant/post-salvage for each arm separately and overall.
SECONDARY OBJECTIVES:
I. To assess the 2-year progression free survival (PFS) and overall survival (OS) in the transplanted population.
II. To assess the complete remission (CR) rate to salvage therapy. III. To assess the CR rate post HDT-ASCT. IV. To assess the post HDT-ASCT partial remission (PR) to CR conversion rate.
SECONDARY IMAGING OBJECTIVES:
I. To assess the % change in TMTV (delta TMTV) from baseline to pre-transplant/post-salvage in predicting response (CR+PR vs no response) at pre-transplant/post-salvage for each arm separately and overall.
II. To assess baseline TMTV and delta TMTV in predicting EFS/OS for each arm separately and overall.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A:
SALVAGE THERAPY: Patients receive 1 of 3 chemotherapy regimens as clinically indicated: 1) ifosfamide intravenously (IV), carboplatin IV, and etoposide IV; 2) gemcitabine IV, vinorelbine IV, and pegylated liposomal doxorubicin IV; or 3) brentuximab vedotin IV and bendamustine IV. Patients then undergo a positron emission tomography (PET)/computed tomography (CT) scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve stable disease (SD) or progressive disease (PD) come off study treatment.
HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo radiation therapy (RT) as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.
MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated.
ARM B:
SALVAGE THERAPY: Patients receive pembrolizumab IV plus 1 of 3 chemotherapy regimens specified in Arm A as clinically indicated. Patients then undergo a PET scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment.
HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant.
MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated.
All patients undergo CT scans during follow-up.
Study Type
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient must be >= 5 years of age and =< 75 years of age
- Patient must have relapsed/refractory classical Hodgkin lymphoma (R/R cHL) after frontline (first line of chemotherapy) as evidenced by Fludeoxyglucose F-18 (FDG) avid on PET scan. If regimen is adjusted based on PET2 results or toxicity during frontline therapy, this will only be considered one line of therapy. Prior checkpoint inhibitor is completed > 6 months prior to randomization
- Patients >= 18 years of age must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2. Pediatric patients (16-17 years of age) must have a Karnofsky performance level >= 50%. Pediatric patients (5-15 years of age) must have a Lansky performance level >= 50
- Patient must be deemed fit for high dose chemo and autologous stem cell transplant
- Patient must have the ability to understand and the willingness to sign a written informed consent document. Pediatric patients (< 18 years of age) and patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible. Child assent must be obtained as appropriate in accordance with institutional guidelines
Absolute neutrophil count (ANC) >= 1000/mcL (must be obtained =< 7 days prior to randomization)
If disease includes marrow involvement or hypersplenism, please reference the below revised requirement:
- ANC >= 500/mcL
Platelets >= 75,000/mcL (must be obtained =< 7 days prior to randomization)
If disease includes marrow involvement or hypersplenism, please reference the below revised requirement:
- Platelets >= 25,000/mcL
- Total bilirubin =< 2x institutional upper limit of normal (ULN) (must be obtained =< 7 days prior to randomization)
- Aspartate aminotransferase (AST)(serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional ULN for age (must be obtained =< 7 days prior to randomization)
Glomerular filtration rate (GFR) >= 50 mL/min/1.73m^2 73m^2 for patients >= 18 years of age (must be obtained =< 7 days prior to randomization)
Pediatric patients (< 18 years old) must have a creatinine clearance OR radioisotope GFR >= 70 mL/min/1.73 m^2 OR serum creatinine below the maximum based on age/gender as follows (derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the Centers for Disease Control and Prevention [CDC]):
- Age: 5 to < 6 years; Maximum Serum Creatinine (mg/dL): Male (0.8); Female (0.8)
- Age: 6 to 10 years; Maximum Serum Creatinine (mg/dL): Male (1.0); Female (1.0)
- Age: 10 to 13 years; Maximum Serum Creatinine (mg/dL): Male (1.2); Female (1.2)
- Age: 13 to < 16 years; Maximum Serum Creatinine (mg/dL): Male (1.5); Female (1.4)
- Age: >= 16 years; Maximum Serum Creatinine (mg/dL): Male (1.7); Female (1.4)
- Patient must have a left ventricular ejection fraction (LVEF) >= 50%, as measured by echocardiogram, multi-gated acquisition (MUGA) scan, or functional cardiac imaging scan (or a shortening fraction of >= 27% for patients < 18 years of age only)
- Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of randomization are eligible for this trial
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients >= 18 years of age with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Exclusion Criteria:
Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.
- All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy.
- A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)
- Patients of childbearing potential and/or sexually active patients must not expect to conceive or father children by using an accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study. Additionally, patients of childbearing potential must continue contraception measures for 4 months after the last dose of pembrolizumab, 6 months after the last dose of vinorelbine and for 3 months after the last dose of bendamustine. Male patients must continue contraception measures for 6 months after the last dose of ifosfamide and for 3 months after the last dose of vinorelbine. Patients must also not breastfeed while on study treatment and for 4 months after the last dose of Pembrolizumab and 9 days after the last dose of vinorelbine
- Patient must not have a history of (non-infectious) pneumonitis/interstitial lung disease that required steroids or have current pneumonitis/interstitial lung disease
Patient must not have the following symptomatic autoimmune disorders: rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus, Sjögren's syndrome, or autoimmune vasculitis (e.g., Wegener's Granulomatosis), or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone). Patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study.
- Replacement doses of steroids for patients with adrenal insufficiency are allowed.
- Additionally, patients must not have an autoimmune disease that is felt by the treating physician to have the potential to be exacerbated by checkpoint inhibition
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Arm A (chemotherapy regimen, HDT-ASCT)
SALVAGE THERAPY: Patients receive 1 of 3 chemotherapy regimens as clinically indicated: 1) ifosfamide IV, carboplatin IV, and etoposide IV; 2) gemcitabine IV, vinorelbine IV, and pegylated liposomal doxorubicin IV; or 3) brentuximab vedotin IV and bendamustine IV. Patients then undergo a PET/CT scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment. HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant. MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated. |
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo RT
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo ASCT
Other Names:
Given IV
Other Names:
Undergo PET/CT
Other Names:
Given IV
Other Names:
Undergo PET/CT and CT
Other Names:
Receive standard preparative chemotherapy regimen
Other Names:
|
|
Experimental: Arm B (chemotherapy regimens+pembrolizumab, HD-ASCT)
SALVAGE THERAPY: Patients receive pembrolizumab IV plus 1 of 3 chemotherapy regimens specified in Arm A as clinically indicated. Patients then undergo a PET scan. Patients who achieve a CR or PR proceed to HDT-ASCT. Patients who achieve SD or PD come off study treatment. HDT-ASCT: Patients undergo ASCT. Patients may also receive a standard preparative chemotherapy regimen as clinically indicated. Patients who achieve PR prior to ASCT may also undergo RT as clinically indicated. Patients who went into ASCT with PR also undergo a PET/CT scan 30 days post-transplant. MAINTENANCE THERAPY: Patients may receive brentuximab vedotin IV as clinically indicated. |
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo RT
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Given IV
Other Names:
Undergo ASCT
Other Names:
Given IV
Other Names:
Undergo PET/CT
Other Names:
Given IV
Other Names:
Undergo PET/CT and CT
Other Names:
Receive standard preparative chemotherapy regimen
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Event free survival (EFS)
Time Frame: Time from randomization to the earlier of events listed in description field, assessed up to 15 years
|
Events include: failure to achieve partial remission (PR) or complete remission (CR) to salvage chemotherapy, failure to achieve a CR post high dose chemotherapy and autologous stem cell transplant (HDT-ASCT), progression, receipt of unplanned radiation or brentuximab vedotin maintenance, or death.
Patients who have not experienced any of these events will be censored at the date they are last known to be progression free.
Kaplan-Meier method will be used to estimate EFS, including medians and confidence intervals.
Comparison of EFS between treatment arms will be conducted based on intent-to-treat principle using a one-sided stratified log-rank test with the stratification factors.
|
Time from randomization to the earlier of events listed in description field, assessed up to 15 years
|
|
Lugano-based response
Time Frame: Pre-transplant/post-salvage therapy
|
Will be assessed using positron emission tomography/computed tomography (PET/CT) scan with Deauville score.
Will assess the diagnostic performance of baseline metabolic tumor volume (TMTV) in predicting response (CR+PR vs no response) at pre-transplant/post-salvage, overall and by study arm.
Diagnostic performance of baseline TMTV will be assessed using area under the receiver operator characteristic curve (ROC AUC) analysis, where the reference standard is pre-transplant/post-salvage response (CR/PR).
|
Pre-transplant/post-salvage therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Percentage change in TMTV (delta TMTV)
Time Frame: Baseline to pre-transplant/post-salvage therapy
|
Similar methods will be used as the primary imaging aim to assess the diagnostic performance of delta TMTV in predicting pre-transplant/post-salvage response (CR+PR vs no response).
Delta TMTV will be defined as the percent change from baseline to pre-transplant/post-salvage [(post-salvage/pre-transplant - baseline)/baseline X 100].
|
Baseline to pre-transplant/post-salvage therapy
|
|
Baseline TMTV and delta TMTV
Time Frame: Baseline and pre-transplant/post-salvage therapy
|
Will assess baseline TMTV and delta TMTV in predicting EFS/overall survival (OS) for each arm separately and overall.
The association between TMTV and EFS will be analyzed through a Cox regression model.
TMTV will be analyzed individually as its absolute value and the percent change from baseline.
We will also test if there is a difference by arm by including an interaction term in the model between TMTV and arm.
The Kaplan-Meier method will be used to estimate EFS, including median survival times and confidence intervals.
In addition to examining the TMTV, we will also analyze standard uptake value maximum (SUVmax) and total lesion glycolysis (TLG) with the same methods.
The OS outcome will be analyzed in a similar manner.
|
Baseline and pre-transplant/post-salvage therapy
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Vaishalee P Kenkre, ECOG-ACRIN Cancer Research Group
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Hodgkin Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Dermatologic Agents
- Antibiotics, Antineoplastic
- Immune Checkpoint Inhibitors
- Keratolytic Agents
- Immunotoxins
- Carboplatin
- Etoposide
- Etoposide phosphate
- Antibodies
- Ifosfamide
- Isophosphamide mustard
- Podophyllotoxin
- Immunoglobulins
- Bendamustine Hydrochloride
- Pembrolizumab
- Doxorubicin
- Liposomal doxorubicin
- Antibodies, Monoclonal
- Antineoplastic Agents, Immunological
- Vinorelbine
- Brentuximab Vedotin
- Immunoconjugates
- Gemcitabine
Other Study ID Numbers
- NCI-2023-00575 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180820 (U.S. NIH Grant/Contract)
- EA4211 (Other Identifier: CTEP)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Classic Hodgkin Lymphoma
-
Guangzhou Gloria Biosciences Co., Ltd.Not yet recruitingRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Classic Hodgkin's Lymphoma
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin LymphomaUnited States
-
National Cancer Institute (NCI)SuspendedRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)RecruitingRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin LymphomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Classic Hodgkin Lymphoma | Refractory Classic Hodgkin LymphomaUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Recurrent Classic Hodgkin Lymphoma | Refractory... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnn Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma | Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IV... and other conditionsUnited States, Canada, Puerto Rico
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingClassic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Classic Hodgkin LymphomaUnited States
-
Stanford UniversityMerck Sharp & Dohme LLCRecruitingHodgkin Lymphoma | Classic Hodgkin Lymphoma | Refractory Classic Hodgkin Lymphoma | Relapsed Classical Hodgkin LymphomaUnited States
Clinical Trials on Carboplatin
-
Eisai Inc.CompletedCancerUnited States, Austria, India
-
Samyang Biopharmaceuticals CorporationCompleted
-
NHS Greater Glasgow and ClydeCompletedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity CancerUnited Kingdom, Australia, New Zealand
-
Duke UniversityCompletedBrain and Central Nervous System TumorsUnited States, Canada
-
National Cancer Institute (NCI)CompletedBreast Cancer | Ovarian CancerUnited States
-
National Cancer Institute (NCI)Children's Oncology GroupCompletedBrain and Central Nervous System TumorsUnited States, Canada, Puerto Rico, Australia, Netherlands, New Zealand, Switzerland
-
All India Institute of Medical Sciences, New DelhiCouncil of Scientific and Industrial Research, IndiaUnknownIntraocular RetinoblastomaIndia
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Eli Lilly and CompanyCompletedLung NeoplasmsUnited States
-
MEI Pharma, Inc.CompletedPeritoneal Neoplasms | Ovarian Cancer | Fallopian Tube CancerUnited States, Spain, Belgium, United Kingdom, Australia, Italy, Poland